Lianhuan Pharmaceutical (600513.SH): Bilastine API approved for marketing

Zhitongcaijing · 2d ago

Zhitong Finance App News, Lianhuan Pharmaceutical (600513.SH) issued an announcement. Recently, the company received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active ingredient bilastine issued by the State Drug Administration. Bilastine is a non-sedative long-acting antihistamine that selectively antagonizes peripheral H1 receptors, and has no affinity for muscarinic receptors and low affinity for other receptors.

The company's bilastine API obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”, indicating that the API has passed the review and approval, complies with the requirements of the relevant regulations on domestic drug registration, which is conducive to enriching the company's product line.